Levetiracetam Cinfa

Levetiracetam, the active ingredient in Levetiracetam Cinfa, is an antiepileptic presented as an oral tablet for oral use. It is employed to control various seizure types in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam Cinfa is an antiepileptic drug indicated for several seizure disorders. It helps reduce the frequency and severity of seizures in the following conditions: - Partial‑onset seizures: provides adjunctive control of focal seizures with or without secondary generalization. - Generalized tonic‑clonic seizures: reduces the occurrence of bilateral convulsive episodes. - Myoclonic seizures: diminishes rapid, brief muscle jerks characteristic of this seizure type.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: generalized tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare but serious skin disorder. - Blood dyscrasias: neutropenia or thrombocytopenia. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Rash with systemic symptoms: may indicate a hypersensitivity reaction. - Depression: new or worsening mood disturbances.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: assess creatinine clearance and adjust dose if necessary. - Pregnancy: risk category is unknown; weigh potential benefits against unknown fetal risk. - Breastfeeding: evaluate infant exposure versus maternal benefit. - Concomitant CNS depressants: monitor for additive sedation. - Mood changes: observe for depression or suicidal ideation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam has a relatively low interaction profile, but certain combinations require attention.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations. - Phenytoin: potential decrease in levetiracetam exposure. - Phenobarbital: can lower levetiracetam levels.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression. - Other antiepileptics (e.g., valproate): may increase sedation. - Antidepressants or antipsychotics: watch for mood alterations. - Sedating antihistamines: possible enhanced drowsiness. - Opioids: monitor for increased respiratory depression.